News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
731,913 Results
Type
Article (42041)
Company Profile (314)
Press Release (689545)
Multimedia
Podcasts (82)
Webinars (17)
Section
Business (207439)
Career Advice (2078)
Deals (35859)
Drug Delivery (113)
Drug Development (82252)
Employer Resources (175)
FDA (16457)
Job Trends (15124)
News (350529)
Policy (33024)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2594)
Accelerated approval (31)
Adcomms (24)
Allergies (139)
Alliances (50473)
ALS (171)
Alzheimer's disease (1673)
Antibody-drug conjugate (ADC) (308)
Approvals (16723)
Artificial intelligence (511)
Autoimmune disease (145)
Automation (37)
Bankruptcy (364)
Best Places to Work (11708)
BIOSECURE Act (21)
Biosimilars (188)
Biotechnology (212)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (635)
Cancer (4797)
Cardiovascular disease (395)
Career advice (1759)
Career pathing (35)
CAR-T (280)
CDC (44)
Celiac Disease (2)
Cell therapy (746)
Cervical cancer (36)
Clinical research (70202)
Collaboration (1706)
Company closure (4)
Compensation (1152)
Complete response letters (52)
COVID-19 (2737)
CRISPR (91)
C-suite (835)
Cystic fibrosis (143)
Data (6216)
Decentralized trials (2)
Denatured (25)
Depression (134)
Diabetes (498)
Diagnostics (6707)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (247)
Drug pricing (186)
Drug shortages (28)
Duchenne muscular dystrophy (227)
Earnings (90581)
Editorial (57)
Employer branding (21)
Employer resources (153)
Events (120202)
Executive appointments (977)
FDA (19560)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1473)
Gene editing (197)
Generative AI (45)
Gene therapy (602)
GLP-1 (968)
Government (4680)
Grass and pollen (6)
Guidances (383)
Healthcare (18975)
HIV (56)
Huntington's disease (45)
IgA nephropathy (81)
Immunology and inflammation (245)
Immuno-oncology (55)
Indications (105)
Infectious disease (2997)
Inflammatory bowel disease (188)
Inflation Reduction Act (14)
Influenza (111)
Intellectual property (246)
Interviews (321)
IPO (16755)
IRA (49)
Job creations (3757)
Job search strategy (1475)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (548)
Leadership (31)
Legal (8024)
Liver cancer (91)
Longevity (15)
Lung cancer (643)
Lymphoma (375)
Machine learning (43)
Management (59)
Manufacturing (792)
MASH (161)
Medical device (13778)
Medtech (13830)
Mergers & acquisitions (20166)
Metabolic disorders (1261)
Multiple sclerosis (157)
NASH (16)
Neurodegenerative disease (311)
Neuropsychiatric disorders (87)
Neuroscience (2896)
Neurotech (1)
NextGen: Class of 2026 (6597)
Non-profit (4538)
Now hiring (65)
Obesity (592)
Opinion (270)
Ovarian cancer (164)
Pain (196)
Pancreatic cancer (227)
Parkinson's disease (283)
Partnered (33)
Patents (491)
Patient recruitment (477)
Peanut (56)
People (59922)
Pharmaceutical (67)
Pharmacy benefit managers (29)
Phase 1 (21972)
Phase 2 (30942)
Phase 3 (22905)
Pipeline (5117)
Policy (280)
Postmarket research (2573)
Preclinical (9340)
Press Release (71)
Prostate cancer (236)
Psychedelics (47)
Radiopharmaceuticals (279)
Rare diseases (826)
Real estate (6120)
Recruiting (71)
Regulatory (24642)
Reports (51)
Research institute (2419)
Resumes & cover letters (359)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (147)
Series A (245)
Series B (191)
Service/supplier (11)
Sickle cell disease (99)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3722)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (86)
The Weekly (55)
Vaccines (991)
Venture capital (89)
Weight loss (382)
Women's health (87)
Worklife (18)
Date
Today (37)
Last 7 days (591)
Last 30 days (2001)
Last 365 days (30193)
2026 (2886)
2025 (30617)
2024 (35641)
2023 (40434)
2022 (51647)
2021 (56118)
2020 (54492)
2019 (46923)
2018 (35362)
2017 (32532)
2016 (32058)
2015 (38042)
2014 (31819)
2013 (26857)
2012 (29169)
2011 (29836)
2010 (27941)
Location
Africa (766)
Alabama (83)
Alaska (7)
Arizona (308)
Arkansas (13)
Asia (40168)
Australia (6695)
California (11283)
Canada (3260)
China (1102)
Colorado (475)
Connecticut (476)
Delaware (334)
Europe (87226)
Florida (1664)
Georgia (356)
Hawaii (3)
Idaho (61)
Illinois (880)
India (62)
Indiana (516)
Iowa (23)
Japan (421)
Kansas (129)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1376)
Massachusetts (8122)
Michigan (321)
Minnesota (626)
Mississippi (5)
Missouri (125)
Montana (34)
Nebraska (28)
Nevada (121)
New Hampshire (79)
New Jersey (2996)
New Mexico (29)
New York (2975)
North Carolina (1472)
North Dakota (9)
Northern California (5502)
Ohio (330)
Oklahoma (21)
Oregon (41)
Pennsylvania (2272)
Puerto Rico (22)
Rhode Island (47)
South America (1148)
South Carolina (65)
South Dakota (1)
Southern California (4383)
Tennessee (172)
Texas (1737)
United States (40038)
Utah (340)
Vermont (1)
Virginia (259)
Washington D.C. (81)
Washington State (933)
West Virginia (4)
Wisconsin (108)
Wyoming (2)
731,913 Results for "stellar biotechnologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
January 8, 2026
·
10 min read
Press Releases
Cancer Immunotherapy Market Size to Hit USD 700.09 Billion by 2034, Growing at a Stellar 11.95% CAGR
December 1, 2025
·
1 min read
Press Releases
Pancreatic Cancer Diagnostic Market Size to Reach USD 9.76 Billion by 2034, Growing at a Stellar 13.8% CAGR
December 1, 2025
·
1 min read
Press Releases
Ultomiris Drug Market Size to Hit USD 48.61 Billion by 2034, Growing at a Stellar 28.5% CAGR
November 24, 2025
·
1 min read
Orbus Therapeutics Announces Publication of Phase 3 STELLAR Clinical Study Results Showing Clinically Meaningful Improvements in Rare Brain Tumor in Journal of Clinical Oncology (JCO)
December 3, 2025
·
5 min read
Press Releases
Orbus Therapeutics Highlights Phase 3 STELLAR Clinical Study Results Showing Clinically Meaningful Benefits in Rare Brain Tumor at Society for Neuro-Oncology (SNO) Annual Meeting
November 21, 2025
·
5 min read
Press Releases
Lumenis Launches New Stellar M22™ Skin Treatments Platform with XPL™ Technology Backed by New Clinical Data at the Annual American Society for Dermatologic Surgery Meeting (ASDS)
November 19, 2025
·
5 min read
Press Releases
Orbus Therapeutics Announces Oral Presentation of Updated Results With Blinded Independent Central Review from the Phase 3 STELLAR Clinical Trial at the Society for Neuro-Oncology Annual Meeting
November 10, 2025
·
1 min read
Cancer
Exelixis’ Kinase Blocker Sets ‘New Survival Bar’ in Third-Line Colorectal Cancer, Opening Road to FDA
With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for zanzalintinib.
October 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
October 20, 2025
·
10 min read
1 of 73,192
Next
